Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting
NRTX-1001 has been well-tolerated to date in all treated subjects, and neuropsychological testing suggests the absence of detectable neurocognitive impairment.
- NRTX-1001 has been well-tolerated to date in all treated subjects, and neuropsychological testing suggests the absence of detectable neurocognitive impairment.
- “The emerging data demonstrate that administration of NRTX-1001 is well-tolerated and has the potential to significantly reduce seizure frequency,” said John Hixson, M.D., senior medical director at Neurona.
- “We are very encouraged by the data from these first subjects, who continue to exhibit durable seizure suppression for up to 21 months post-administration.
- Baseline monthly seizure frequency was established by reviewing subjects’ medical history from the six months prior to the administration of NRTX-1001.